CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL
PR Newswire•23/10/2026•09:05 ET
2
Key Highlights
- ➤Cumberland Pharmaceuticals (CPIX) will update ifetroban’s potential DMD cardiomyopathy treatment on October 26
- ➤Webcast registration link updated for Cumberland’s ifetroban DMD program call
- ➤Ifetroban clinical programs also evaluate systemic sclerosis, idiopathic pulmonary fibrosis and cancer metastasis
CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL PR Newswire
NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, confirmed that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").
Get started
Create a free account to read the full story.